{"id":"W2318409487","doi":"10.1111/igc.0b013e3181e273a8","title":"Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Sorafenib; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Ovarian cancer; Adverse effect; Toxicity; Clinical endpoint; Chemotherapy; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009888253,0.0005527162,0.002591339,0.0007249719,0.0004029891,0.0007527059,0.0004847902,0.0006165001,0.00223914],"category_scores_gemma":[0.001645592,0.000314044,0.001125047,0.0006946308,0.0003264289,0.000652931,0.0004869753,0.001670288,0.0003810999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007601956,"about_ca_system_score_gemma":0.0007603043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001222856,"about_ca_topic_score_gemma":0.005241842,"domain_scores_codex":[0.9995153,0.0002480698,0.00005951462,0.00004001816,0.00005111396,0.00008604583],"domain_scores_gemma":[0.9994813,0.0001687079,0.00008757793,0.00004118572,0.00002465702,0.000196616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2082122,0.005464567,0.02612868,0.002603406,0.003614345,0.003669781,0.0008481083,0.008875668,0.03138679,0.0008110375,0.007818589,0.7005668],"study_design_scores_gemma":[0.1611704,0.431196,0.2390443,0.001023451,0.009482729,0.02197049,0.001600025,0.02198497,0.04028115,0.002042751,0.06983966,0.0003640942],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.974874,0.01983753,0.0003015944,0.001048975,0.0004066401,0.0001737322,0.0002098312,0.0001222437,0.003025553],"genre_scores_gemma":[0.9939435,0.004209841,0.0002968204,0.0001347224,0.0001450812,0.00006145305,0.0001878753,0.00001565721,0.001005035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002591339,"threshold_uncertainty_score":0.007490635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01911840457621101,"score_gpt":0.3281520081814268,"score_spread":0.3090336036052158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}